Treatment of heterozygous familial hypercholesterolemia: Atorvastatin vs simvastatin

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 11, Issue 1, 2001, Pages 17-24

  Bo, M ^a,c   Nicolello, M T ^a   Fiandra, U ^a   Mercadante, G ^a   Piliego, T ^b   Fabris, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Medical Department   (Italy)

^c Sezione di Scienze Radiologiche   (Italy)

Author keywords

Atorvastatin; Familial hypercholesterolemia; Fibrinogen; Simvastatin

Indexed keywords

APOLIPOPROTEIN; ATORVASTATIN; FIBRINOGEN; HEPTANOIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENETICS; HETEROZYGOTE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOGEN; HEPTANOIC ACIDS; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0035258480     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Goldstein JL, Hobbs HH, Brown MS (1994) Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease, vol. III. Mc Graw-Hill, New York, pp 1981-2030
2. Scientific Steering Committee of the Simone Broome Register Group (1991) Risk of fatal coronary heart disease in familial hypercholesterolemia. Br Med J 303: 893-896
3. Farnier M, Davignon J (1998) Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 82: 3J-10J
4. Illingworth DR, Bacon S (1989) Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Arteriosclerosis 9 (suppl. 1): I121-I134
5. Illingworth DR (1993) How effective is drug therapy in heterozygous familial hypercholesterolemia? Am J Cardiol 72: 54D-58D
6. Kitano Y, Thompson GR (1993) Role of LDL apheresis in the management of hypercholesterolemia. Transfus Sci 14: 269-280
7. Donner MG, Richter WO, Schwandt P (1997) Long term effect of LDL apheresis on coronary heart disease. Eur J Med Res 2: 270-274
8. Bambauer R, Olbricht CJ, Schoeppe E (1997) Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results. Ther Apher 1: 242-248
9. Grundy SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319: 24-32
10. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D (1997) Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 79: 1475-1481
11. Wolffenbuttel BH, Mahla G, Muller D, Pentrup A, Black DM (1998) Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. Neth J Med 52: 131-137
12. Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschini G, Sirtori CR (1995) Therapy with HMG-CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Atherosclerosis 117:189-198
13. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM (1995) Reduction of LDL-C by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15: 678-682
14. Dart A, Jerums G, Nicholson G, D'Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Bracs P, Black D (1997) A multicenter, double blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 80: 39-44
15. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81: 582-587
16. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J (1997) Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 17: 1527-1531
17. Hoogerbrugge N (1998) Effects of atorvastatin on serum lipids of patients with familial hypercholesterolemia. J Intern Med 244: 143-147
18. Lea AP, McTavish D (1997) Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 53: 828-847
19. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (1993) Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269: 3015-3023
20. Andersen LK, Jensen HK, Juul S, Faergeman O (1997) Patients' attitudes toward detection of heterozygous familial hypercholesterolemia. Arch Intern Med 157: 553-560
21. Sanchez-Quesada JL, Otal-Entraigas C, Franco M, Jorba O, Gonzalez-Sastre F, Blanco-Vaca F, Ordonez-Llanos J (1999) Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 84: 655-659
22. Beigel Y, Fuchs J, Snir M, Lurie Y, Green P, Djaldetti M (1991) Lovastatin therapy in heterozygous familial hypercholesterolaemic patients: effect on blood rheology and fibrinogen levels. J Intern Med 230: 23-27
23. Friedewald WT, Levy RI, Frederickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502
24. American Heart Association (1986) Recommendation for the treatment of hypercholesterolemia. Circulation 69: 1065A-1090A
25. Schuster H, Luft FC (1998) Clinical criteria versus DNA diagnosis in heterozygous familial hypercholesterolemia. Is molecular diagnosis superior to clinical diagnosis? Arterioscler Thromb Vasc Biol 18: 331-332
26. Koivisto PVI, Koivisto UM, Miettinen TA, Kontula K (1992) Diagnosis of heterozygous familial hypercholesterolemia. DNA analysis complements clinical examination and analysis of serum lipid levels. Arterioscler Thromb Vasc Biol 12: 584-592
27. Russel DW, Esser V, Hobbs H (1989) Molecular basis of familial hypercholesterolemia. Arteriosclerosis 9 (suppl I): I-8-I-13
28. Bild DE, Williams RR, Brewer HB, Herd JA, Pearson TA, Stein E (1993) Identification and management of heterozygous familial hypercholesterolemia: Summary and recommendations from an NHLBI Workshop. Am J Cardiol 72: 1D-5D
29. Hagemenas FC, Pappu AS, Illingworth DR (1990) The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolemia. Eur J Clin Invest 20: 150-157
30. Quiney J, Watts GF, Kerr-Muir M, Slavin B, Lewis B (1992) One year experience in the treatment of familial hypercholesterolemia with simvastatin. Postgrad Med J 68: 575-580
31. Black DM, Bakker-Arkema RG, Nawrocki JW (1998) An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA Reductase Inhibitor. Arch Intern Med 58: 577-584
32. Illingworth DR, Bacon S, Pappu AS, Sexton GJ (1992) Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 96: 53-64
33. Mol TM, Erkelens DW, Leuven JAG (1988) Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia. Atherosclerosis 69: 131-137
34. Bo M, Bonino F, Neirotti M, Gottero M, Pernigotti L, Molaschi M, Fabris F (1991) Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 42: 106-113
35. Black DM (1998) Statins and fibrinogen. Lancet 351: 1430
36. Darko DA, O'Shea D (1998) Statins and fibrinogen. Lancet 351: 1431
37. Athyros VG (1998) Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolemia. Clin Drug Invest 16: 219-227
38. Dujovne CA, Overhiser RW, Harris WS (1996) Changes in haemorheology and atherothrombotic parameters by improving serum lipids in atorvastatin-treated hyperlipidaemics. In: 66th Congress of the European Atherosclerosis Society (Florence, July 13-17, 1996). Giovanni Lorenzini Medical Foundation, abstract.
39. Davignon J (1998) Advances in drug treatment of dyslipidemia: focus on Atorvastatin. Can J Cardiol 14 (Suppl. B): 28B-38B
40. Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, Kivel F, Black DM (1996) Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Therapeut 1: 117-122
41. Erkelens DW, Baggen MG, Van Doormaal JJ, Kettner M, Koningsberger JC, Mol MJ (1998) Clinical experience with simvastatin compared with cholestyramine. Drugs 36 (Suppl. 3): 87-92
42. Geiss HC, Parhofer KG, Schwandt P (1999) Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolemia treated by regular LDL apheresis. J Intern Med 245: 47-55